ALLERGY TREATMENT MARKET ANALYSIS

The major factors that are expected to hinder the growth of the global allergy treatment market include the termination of clinical trial study. For instance, in November 2022, a clinical trial of Tree MATA MPL or Tree MATA immunotherapy for allergic rhinitis and type I hypersensitivity I was terminated due to the poor enrollment of subjects. The clinical trial was sponsored by Allergy Therapeutics, a manufacturer of subcutaneous and sublingual immunotherapy treatments.

Market Opportunities – Increasing Research and Development Activities by Key Market Players

Increasing research and development activities by market players is expected to offer lucrative growth opportunities over the forecast period. For instance, in August 2023, Inimmune Corporation (“Inimmune”), a clinical-stage company focused on the development of innovative immunotherapeutics, announced that the first subject has been dosed in Inimmune’s phase 1/1b First-in-Human clinical trial of INI-2004, Inimmune’s TLR4 agonist product candidate under development as a potential treatment of allergic rhinitis. The phase 1/1b trial is a randomized, double-blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of INI-2004 in healthy volunteers and participants with allergic rhinitis (AR).